Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ciclesonide for the treatment of airway disease in horses

a technology of airway disease and ciclesonide, which is applied in the field of medicine, can solve the problems of state of the art treatment with dexamethasone not allowing constant high dose levels, etc., and achieves the effects of reducing the risk of infection, increasing susceptibility to infections, and convenient treatmen

Inactive Publication Date: 2014-06-26
BOEHRINGER LNGELHEIM VETMEDICA GMBH
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for treating airway diseases in horses using ciclesonide or a pharmaceutically acceptable salt thereof or a composition comprising ciclesonide. The use of ciclesonide has advantages such as reduced side effects, minimized risks associated with complications, and a more convenient treatment option compared to other glucocorticoids. The treatment results in a beneficial therapeutic effect in horses with airway disease and the prodrug nature of ciclesonide allows for its conversion into the effective molecule C21-C21-desisobutyrylciclesonide in horses. Additionally, ciclesonide undergoes reversible fatty acid esterifications with fatty acids in human lung tissue, which may serve as a depot.

Problems solved by technology

This can lead to increased susceptibility to infections.
The state of the art treatment with dexamethasone does not allow the administration of constantly high dose levels for a longer time period due to the risk of developing side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ciclesonide for the treatment of airway disease in horses
  • Ciclesonide for the treatment of airway disease in horses
  • Ciclesonide for the treatment of airway disease in horses

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0085]Budesonide is investigated in a cross-over, blinded moldy hay challenge study. Eight (8) RAO horses are examined in the study, which is divided into an acclimation and a treatment phase. Placebo for budesonide is administered a few times per inhalation via the Equine Inhaler device to all horses in the acclimation period. Budesonide and dexamethasone is administered to the horses in a cross-over design in the treatment phase. The horses are challenged by exposure to moldy hay throughout the acclimation and treatment periods. Budesonide is administered with the doses of 450 μg (2 actuations) / 900 μg (4 actuations) / 1800 (8 actuations) μg / horse (ex-RESPIMAT®) twice daily for 14 days per inhalation via the Equine Inhaler device. Nozzle A and a RESPIMAT® inhaler device not available commercially is used in the study. Nozzle A is the nozzle used with the commercially available RESPIMAT®. Dexamethasone is administered with a dose of 0.066 mg / kg per os, once daily for 14 days. Lung fun...

example 2

1st Ciclesonide Study

[0087]Ciclesonide is investigated in a cross-over, blinded moldy hay challenge study. Eight (8) RAO horses are examined in the study, which is divided into an acclimation and a treatment phase. Placebo for ciclesonide is administered twice daily per inhalation via the Equine Inhaler device to all horses for 1 week in the acclimation period. Ciclesonide and dexamethasone are administered to the horses in a cross-over design in the treatment phase. The horses are challenged by exposure to moldy hay throughout the acclimation and treatment periods. Ciclesonide is administered with the doses of 450 μg (2 actuations) / 900 μg (4 actuations) / 1800 μg (8 actuations) / horse (ex-RESPIMAT®) twice daily for 14 days per inhalation via the Equine Inhaler device. Nozzle A and a commercially available RESPIMAT® is used in the study. Dexamethasone is administered with a dose of 0.066 mg / kg per os, once daily for 14 days. Lung function variables (change in transpulmonary pressure (Δ...

example 3

2nd Ciclesonide Study

[0090]Ciclesonide is investigated in a cross-over, blinded moldy hay challenge study. Eight (8) RAO horses are examined in the study, which is divided into an acclimation and a treatment phase. Placebo for ciclesonide is administered twice daily per inhalation via the Equine Inhaler device to all horses for 1 week in the acclimation period. Ciclesonide and dexamethasone are administered to the horses in a cross-over design in the treatment phase. The horses are challenged by exposure to moldy hay throughout the acclimation and treatment periods. Ciclesonide is administered with the doses of 1687.5 μg (5 actuations, nozzle B) / 2700 μg (8 actuations, nozzle A) / 2700 μg (8 actuations, nozzle B) / horse (ex-RESPIMAT®) twice daily for 14 days per inhalation via the Equine Inhaler device. The commercially available RESPIMAT® is used in the study. Nozzle A is the nozzle used with the commercially available RESPIMAT® inhaler. Nozzle B is a different nozzle resulting in a re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

Description

FIELD OF THE INVENTION[0001]The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids or inhaled glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).BACKGROUND INFORMATION[0002]Equine airway disease is a prominent disease in many horses. It can be divided into the diseases of the upper and lower airways. There are a number of equine lower airway diseases with noninfectious origin such as RAO (or heaves or equine chronic obstructive pulmonary disease), IAD, SPAOPD and exercise induced pulmonary hemorrhage (EIPH). The latter is typically diagnosed in racehorses. RAO, IAD and SPAOPD are discs eases with an allergic background. Rarely diagnosed ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/58
CPCA61K9/0078A61K9/0073A61K31/58A61P11/00A61K9/008
Inventor ALBRECHT, BALAZSAVEN, MICHAELLAMAR, JANINELANG, INGO
Owner BOEHRINGER LNGELHEIM VETMEDICA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com